Taiyo Holdings targets significant growth, shareholder returns by 2031

Taiyo Holdings has formalized its medium-term management plan for fiscal years 2026 to 2031, targeting significant financial improvements. By the fiscal year ending March 2031, the company aims for consolidated net sales of JPY 1,800 bn, up from JPY 1,190 bn in fiscal year 2025. Operating profit is projected to reach JPY 470 bn (26% margin), a substantial increase from JPY 220 bn (19% margin) in fiscal year 2025. EBITDA is also targeted to rise to JPY 580 bn (32% margin) from JPY 317 bn (27% margin).

A key financial objective is to achieve a Return on Equity (ROE) of 30% by the fiscal year ending March 2031, an increase from 10.6% in fiscal year 2025. The company intends to allocate approximately JPY 600 bn towards new and renewal investments, focusing on its Electronics and Medical/Pharmaceuticals segments. Shareholder returns will prioritize a DOE of 5% or more, with a total shareholder return ratio of 100% until fiscal year 2028.

Strategic initiatives include expanding the Electronics business, improving profitability in the Medical and Pharmaceuticals manufacturing contract business, and reviewing strategic options for the Medical and Pharmaceuticals manufacturing and sales business. The plan also emphasizes the continued growth of ICT&S businesses and the exploration of new growth areas.